ArrowHead Research signs agreement with Shire AG Arrowhead Research announced that it has signed a research collaboration and license agreement with Shire AG, to develop and commercialize targeted peptide-drug conjugates by utilizing Arrowhead's human-derived Homing Peptide platform and Shire's therapeutic payloads. Arrowhead will receive research funding and could be eligible for development, regulatory, and commercialization milestone payments of up to $32.8M for each development candidate, plus additional milestone payments for a second indication, and royalties on worldwide sales. Additional financial terms of the agreement were not disclosed.
News For ARWR From The Last 14 Days
Check below for free stories on ARWR the last two weeks.